retatrutide fatty liver study Triple hormone receptor agonist for metabolic dysfunction-associated steatotic disease: a randomized phase 2a trial Retatrutide may be promising for

Five-year and ten-year data continue to accumulate as more patients enter long-term treatment

doi: 10.1210/en.2004-0419

Do not take a double dose to make up for the missed one

Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome

Using a lower "microdose": Some studies suggest lower doses combined with lifestyle support can still be effective, though this is not a formally approved strategy

Commonly reported injuries include gastroparesis (stomach paralysis), intestinal blockages, gallbladder disease, pancreatitis, and persistent vomiting leading to malnutrition